11 April 2005   
News
Executive Vice President's Message
Contention, Community Mark 'QC for the Future' Workshop
Leadership Conference Highlights Globalization Goals, Challenges
Press Releases
Volunteers Honored for Service at Luncheon
Standards Status
Notice of Vote and Comment Deadlines for Consensus Documents
Recently Approved Documents
Recently Distributed ISO Standards
Seeking Input and Volunteer Participation -- Call for Nominations
Focus on Global Terminology
Events and Exhibits
Calendar of Meetings
Upcoming Events
Membership
Join Us
New and Sustaining Members
Update Your Subscription
 
CLSI Home Page
Search Past Issues
Update Your Contact Information
Print this article Print all articles
 
How do you use CLSI documents?
 

Setting up new assays

 

Reviewing FDA new product submissions

 

Developing products

 

Laboratory inspections by regulatory agencies

 

Professional certification

 

Performing quality control

 

Other




 
Standards Status

Notice of Vote and Comment Deadlines for Consensus Documents
Molecular Diagnostic Methods for Infectious Diseases (MM3-P2); Genotyping for Infectious Diseases (MM10-P); Collection and Handling of Specimens for Molecular Methods (MM13-P)

Clinical and Laboratory Standards Institute announces that the following documents are submitted for vote as candidate-for-advancement consensus documents.


The documents and ballots are posted on Forums to delegates of Active and Associate Active member organizations. If you are a voting delegate or alternate, we request that you access Forums to obtain the candidate-for-advancement document. Login to access Forums.


Molecular Diagnostic Methods for Infectious Diseases (MM3-P2); Proposed Guideline— Second Edition

MM3-P2Molecular Diagnostic Methods for Infectious Diseases:  Proposed Guideline--Second Edition

This guideline addresses topics relating to clinical applications, amplified and non-amplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories. 

The deadline for the completed ballot for MM3-P2 to be received in the Executive Offices is 11 July 2005.


Second Notice

Genotyping for Infectious Diseases (MM10-P); Collection and Handling of Specimens for Molecular Methods (MM13-P)


MM10-PGenotyping for Infectious Diseases: Identification and Characterization; Proposed Guideline
This guideline describes currently used analytical approaches and methodologies applied to identify the clinically important genetic characteristics responsible for disease manifestation, outcome, and response to therapy in the infectious disease setting.  It also provides guidance on the criteria to be considered for design, validation, and determination of clinical utility of such testing.

MM13-PCollection, Transport, Preparation, and Storage of Specimens for Molecular Methods; Proposed Guideline
This document provides guidance related to proper and safe biological specimen collection and nucleic acid isolation and purification.  These topics include methods of collection, recommended storage and transport conditions, and available nucleic acid purification technologies for each specimen/nucleic acid type.

The deadline for the completed ballots for MM10-P and MM13-P to be received in the Executive Offices is 8 June 2005.



Under our Administrative Procedures, a CLSI document approved by the area committee at the first level of the consensus process is submitted to delegates as a “candidate-for-advancement” consensus document. This begins the voting and approval period by the delegates.

As a delegate, your vote is to affirm (or reject) the document for advancement as a CLSI document. Please send your completed ballot to the Executive Offices by the above deadline.

In the consensus process, comments are invited at each publication stage. In each edition, the responsible committee includes a summary of comments on the prior edition and its responses to them. Any comments received on a candidate-for-advancement consensus document as a result of delegate voting and consensus review will be addressed by the committee during the document’s advancement.

Find out more about Active and Associate Active membership.

 

[ return to top ]

For more information or to contact us directly, please visit www.clsi.org
©2005 Clinical and Laboratory Standards Institute